title: Rituximab: how approval history is reflected by a corresponding patent filing strategy.
abstract: Because drug development is not a static process, a drug's market authorisation may change over time. In many cases, the number of indications for which a drug is approved increases. Because this facet of drug development also comes at significant costs, a corresponding patent filing strategy is required to protect these investments. The strategy as applied to rituximab, which is approved for a variety of indications, is discussed in this review.
authors.affiliation: Senior Partner with Michalski • Huettermann Patent Attorneys; Duesseldorf, Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Storz
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000266:history* / Q000627:therapeutic use*; D017277:Drug Approval / Q000266:history* / Q000379:methods; D015195:Drug Design; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007155:Immunologic Factors / Q000266:history* / Q000627:therapeutic use*; D010330:Patents as Topic; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab
keywords: antibody; authorisation; patent; rituximab; strategy